Opiant Pharmaceuticals to Report Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 14, 2022

SANTA MONICA, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals, Inc. (“Opiant” or “Company”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced it will report its financial results for the third quarter ended September 30, 2022, after the financial markets close on Monday, November 14, 2022.  

The Company’s management team is scheduled to host a conference call and webcast at 4:30 p.m. ET on Monday, November 14, 2022. To access the call, please dial 1-877-407-0792 in the U.S. or 1-201-689-8263 outside the U.S. and provide the conference ID number: 13732765. To access the live webcast, please visit https://viavid.webcasts.com/starthere.jsp?ei=1569474&tp_key=bb26315c9c. Following the live webcast, an archived version of the call will be available on the website.

Monday November 14 @ 4:30 pm ET
Domestic: 1-877-407-0792
International: 1-201-689-8263
Conference ID: 13732765
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1569474&tp_key=bb26315c9c

About Opiant Pharmaceuticals, Inc.
Opiant Pharmaceuticals, Inc., the company that developed NARCAN® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose. For more information visit: www.opiant.com.

For Media and Investor Inquiries:
Ben Atkins, Opiant
(310) 598-5410
batkins@opiant.com

Staff

Recent Posts

Hemogenyx Pharmaceuticals PLC – Issue of Equity

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE…

3 hours ago

1933 Industries Announces Maturity of Unsecured Convertible Debentures and Encourages Conversion to Support Continued Growth

VANCOUVER, BC / ACCESS Newswire / December 18, 2025 / 1933 Industries Inc. (the "Company"…

3 hours ago

Bupa Hong Kong has selected Cognizant to deliver an AI-driven BPaaS solution to transform health insurance claims

Strategic collaboration aims to enhance operational efficiency and mitigate risks by transitioning to a business…

6 hours ago

DiagnosTear Signs Non-Binding Term Sheet with Sheba Impact and Ramot to Exclusively License New Eye Imaging Technology, CLARIFY, Enabling Needle-Free Blood Count

Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE:…

12 hours ago

CranioSense Awarded $5.5 Million in Federal Grants to Validate Noninvasive Neurotech

BOSTON, Dec. 17, 2025 /PRNewswire/ -- CranioSense, Inc., a neurotechnology company developing the world's first noninvasive…

12 hours ago

Therap Services Announces 2026 National Conference Schedule: Highlighting New Tools, Best Practices, and Over 250 Specialized Sessions

TORRINGTON, Conn., Dec. 17, 2025 /PRNewswire/ -- Therap Services, the national leader in HIPAA-compliant electronic…

12 hours ago